二甲双胍改善糖尿病视网膜病变机制研究进展
|
摘要
二甲双胍是目前全世界应用最广泛的一种降糖药物,可以降低血糖、调节血脂、改善胰岛素敏感性和预防糖尿病进展。研究表明,二甲双胍还可改善糖尿病视网膜病变的眼底病变情况,并延缓糖尿病相关的血管并发症的发生发展,已经并且正在进行大量的体外和体内研究以及临床试验。糖尿病视网膜病变是最常见的糖尿病微血管并发症之一。近年来,该疾病的发病率增加,因此早期诊断和治疗非常重要。本文对近年来二甲双胍与糖尿病视网膜病变相关的研究进展加以综述。
Metformin is the most widely used hypoglycemic drug in the world,which can reduce blood glucose,regulate blood lipids,improve insulin sensitivity and prevent the progress of diabetes. At the same time,metformin can also improve the fundus of diabetic retinopathy and delay the occurrence and development of diabetes-related vascular complications. A large number of in vitro and in vivo studies and clinical trials have been and are being carried out. Diabetic retinopathy is one of the most common diabetic microvascular complications. In recent years,the incidence of the disease has increased,so early diagnosis and treatment is very important. This paper will review the research progress of metformin related to diabetic retinopathy in recent years.
Metformin is the most widely used hypoglycemic drug in the world,which can reduce blood glucose,regulate blood lipids,improve insulin sensitivity and prevent the progress of diabetes. At the same time,metformin can also improve the fundus of diabetic retinopathy and delay the occurrence and development of diabetes-related vascular complications. A large number of in vitro and in vivo studies and clinical trials have been and are being carried out. Diabetic retinopathy is one of the most common diabetic microvascular complications. In recent years,the incidence of the disease has increased,so early diagnosis and treatment is very important. This paper will review the research progress of metformin related to diabetic retinopathy in recent years.
引文
[1] DUSTIN R M,LAURA O,NICHOLAS W C,et al. Functional changes in the neural retina occur in the absence ofmitochondrial dysfunction in a rodent model of diabetic retinopathy[J]. J Neurochem,2017,143(5):595.
[2] ZHANG G H,CHEN H Y,CHEN W Q,et al. Prevalence and risk factors fordiabetic retinopathy in China:a multihospital-based cross-sectional study[J]. Br J Ophthalmol,2017,101(12):1591.
[3] TING D S,CHEUNG G C,WONG T Y. Diabetic retinopathy:global prevalence,major risk factors,screening practices and public health challenges:a review[J]. Clin Exp Ophthalmol,2016,44(4):260.
[4] YANG Q,GRAHAM TE,MODY N,et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes[J]. Nature,2005,436(7049):356-362.
[5]刘路宏.糖尿病视网膜病变研究进展[J].广西医学,2005,27(2):161-164.
[6] FARJO K M,FARJO R A,HALSEY S,et al. Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase-and nuclear factor kappa B-dependent and retinolindependent mechanism[J]. Mol Cell Biol,2012,32(24):5103-5115.
[7] DU M,OTALORA L,MARTIN A,et al. Transgenic mice overexpressing serum retinol-binding protein develop progressive retinal degeneration through a retinoid-independent mechanism[J]. Mol Cell Biol,2015,35(16):2771-2789.
[8] FORETZ M,GUIGAS B,BERTRAND L,et al. Metformin:From mechanisms of action to therapies[J]. Cell Metab,2014,20(6):953-966.
[9] CHAE Y K,ARYA A,MALECEK M K,et al. Repurposing metformin for cancer treatment:current clinical studies[J].Oncotarget,2016,7(26):40767-40780.
[10] KINAAN M,DING H. Metformin:An old drug for the treatment of diabetesbut a new drug for the protection of the endothelium[J].Med Prin Pract,2015,24(5):401-415.
[11] MATHER K J,VERMA S,ANDERSON T J. Improved endothelial functionwith metformin in type 2 diabetes mellitus-reply[J]. J Am Coll Cardiol,2001,37(5):1344-1350.
[12] DE JAGER J,KOOY A,SCHALKWIJK C,et al. Long-term effects of metforminon endothelial function in type 2 diabetes:a randomized controlled trial[J]. J Intern Med,2014,275(1):59-70.
[13]尹清风,陈雪辉,白立炜,等.二甲双胍对背景期糖尿病视网膜病变患者血清维生素D水平的影响[J].中国医师杂志,2017,19(10):1479.
[14]于洋.二甲双胍联合Bevacizumab对大鼠糖尿病视网膜病变的作用及其对VEGF和p AMPK表达的影响[D].沈阳:辽宁医学院,2015.
[15]任志刚.骨化三醇对糖尿病大鼠视网膜TGF-β1,VEGF表达水平的影响[D].乌鲁木齐:新疆医科大学,2011.
[16] GU A,LU J,WANG W,et al. Role of miR-497 in VEGF-Amediated cancer cell growth and invasion in non-small cell lung cancer[J]. Int J Biochem Cell B,2016,70(1):118-125.
[17] YI Q Y,DENG G,CHEN N,et al. Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A[J]. Am J Transl Res,2016,8(9):3947-3954.
[18] ZHANG Y,CHEN F,WANG L. Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p[J]. Am J Transl Res,2017,9(12):5558-5566.
[19] MALEKI C'S,KUSTURICA J,GUI C'E,et al. Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes-observational study[J]. Acta Med Acad,2017,46(2):116-123.
[20] KERN T S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy[J]. J Diabetes,2014,2007(1):95-103.
[2] ZHANG G H,CHEN H Y,CHEN W Q,et al. Prevalence and risk factors fordiabetic retinopathy in China:a multihospital-based cross-sectional study[J]. Br J Ophthalmol,2017,101(12):1591.
[3] TING D S,CHEUNG G C,WONG T Y. Diabetic retinopathy:global prevalence,major risk factors,screening practices and public health challenges:a review[J]. Clin Exp Ophthalmol,2016,44(4):260.
[4] YANG Q,GRAHAM TE,MODY N,et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes[J]. Nature,2005,436(7049):356-362.
[5]刘路宏.糖尿病视网膜病变研究进展[J].广西医学,2005,27(2):161-164.
[6] FARJO K M,FARJO R A,HALSEY S,et al. Retinol-binding protein 4 induces inflammation in human endothelial cells by an NADPH oxidase-and nuclear factor kappa B-dependent and retinolindependent mechanism[J]. Mol Cell Biol,2012,32(24):5103-5115.
[7] DU M,OTALORA L,MARTIN A,et al. Transgenic mice overexpressing serum retinol-binding protein develop progressive retinal degeneration through a retinoid-independent mechanism[J]. Mol Cell Biol,2015,35(16):2771-2789.
[8] FORETZ M,GUIGAS B,BERTRAND L,et al. Metformin:From mechanisms of action to therapies[J]. Cell Metab,2014,20(6):953-966.
[9] CHAE Y K,ARYA A,MALECEK M K,et al. Repurposing metformin for cancer treatment:current clinical studies[J].Oncotarget,2016,7(26):40767-40780.
[10] KINAAN M,DING H. Metformin:An old drug for the treatment of diabetesbut a new drug for the protection of the endothelium[J].Med Prin Pract,2015,24(5):401-415.
[11] MATHER K J,VERMA S,ANDERSON T J. Improved endothelial functionwith metformin in type 2 diabetes mellitus-reply[J]. J Am Coll Cardiol,2001,37(5):1344-1350.
[12] DE JAGER J,KOOY A,SCHALKWIJK C,et al. Long-term effects of metforminon endothelial function in type 2 diabetes:a randomized controlled trial[J]. J Intern Med,2014,275(1):59-70.
[13]尹清风,陈雪辉,白立炜,等.二甲双胍对背景期糖尿病视网膜病变患者血清维生素D水平的影响[J].中国医师杂志,2017,19(10):1479.
[14]于洋.二甲双胍联合Bevacizumab对大鼠糖尿病视网膜病变的作用及其对VEGF和p AMPK表达的影响[D].沈阳:辽宁医学院,2015.
[15]任志刚.骨化三醇对糖尿病大鼠视网膜TGF-β1,VEGF表达水平的影响[D].乌鲁木齐:新疆医科大学,2011.
[16] GU A,LU J,WANG W,et al. Role of miR-497 in VEGF-Amediated cancer cell growth and invasion in non-small cell lung cancer[J]. Int J Biochem Cell B,2016,70(1):118-125.
[17] YI Q Y,DENG G,CHEN N,et al. Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A[J]. Am J Transl Res,2016,8(9):3947-3954.
[18] ZHANG Y,CHEN F,WANG L. Metformin inhibits development of diabetic retinopathy through microRNA-497a-5p[J]. Am J Transl Res,2017,9(12):5558-5566.
[19] MALEKI C'S,KUSTURICA J,GUI C'E,et al. Metformin use associated with protective effects for ocular complications in patients with type 2 diabetes-observational study[J]. Acta Med Acad,2017,46(2):116-123.
[20] KERN T S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy[J]. J Diabetes,2014,2007(1):95-103.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |